IsoRay, Inc. (DE) (ISR) News

IsoRay, Inc. (DE) (ISR): $0.40

0.00 (0.97%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ISR News Items

ISR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ISR News Highlights

  • ISR's 30 day story count now stands at 3.
  • Over the past 18 days, the trend for ISR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • BODY, SEED and WASH are the most mentioned tickers in articles about ISR.

Latest ISR News From Around the Web

Below are the latest news stories about ISORAY INC that investors may wish to consider to help them evaluate ISR as an investment opportunity.

Isoray Announces Results of Fiscal 2023 Annual Meeting of Stockholders

Stockholders Approve Proposal One Clearing Way for Consummation of MergerRICHLAND, Wash., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced the results of its adjourned Fiscal 2023 Annual Meeting of Stockholders which was held on January 27, 2023. The stockholders approved Proposal One which amends the Company’s Certificate of Incorporation

Yahoo | January 30, 2023

Why Isoray Inc. (AMEX: ISR) Stock Shouldn’t Be Ignored In 2023

In the last trading session, 92374.0 shares of the Isoray Inc. (AMEX:ISR) were traded, and its beta was 1.36. Most recently the company’s share price was $0.29, and it changed around $0.0 or 0.88% from the last close, which brings the market valuation of the company to $40.60M. ISR currently trades at a discount to … Why Isoray Inc. (AMEX: ISR) Stock Shouldn’t Be Ignored In 2023 Read More »

Marketing Sentinel | January 16, 2023

Isoray Announces Adjournment of Annual Meeting of Stockholders to January 27, 2023

RICHLAND, Wash., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the January 12th, 2023, adjourned Annual Meeting of Stockholders is being adjourned until January 27th, 2023, to provide stockholders who have not yet voted with additional time to vote on Proposal 1, approval of an amendment to the Company’s Certificate of Incorporatio

Yahoo | January 12, 2023

AMENDED: Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2023

RICHLAND, Wash., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the December 13th, 2022, Annual Meeting is being adjourned until January 12th, 2023, to provide stockholders with additional time to vote on Proposal 1, approval of an amendment to the Company's Certificate of Incorporation to increase the total number of authorized sha

Yahoo | December 14, 2022

Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2022

RICHLAND, Wash., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that the December 13th, 2022, Annual Meeting is being adjourned until January 12th, 2023, to provide stockholders with additional time to vote on Proposal 1, approval of an amendment to the Company’s Certificate of Incorporation to increase the total number of authorized sha

Yahoo | December 14, 2022

Vapotherm, Redwire And These 2 Penny Stocks Insiders Are Aggressively Buying

The Dow Jones closed lower by nearly 500 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company''s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga''s insider transactions platform. Isoray The Trade: Isoray, Inc. (NASDAQ: ISR ) CFO Jonathan Hunt bought a total of 85,404 shares at an average price of $0.38. To acquire these shares, it cost around $32.5 thousand. What’s Happening: The company, last month, said revenue … Full story available on Benzinga.com

Benzinga | December 6, 2022

ISORAY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Isoray, Inc - ISR

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Isoray, Inc (“the Company”) (NYSE: ISR) with Viewpoint Molecular Targeting, Inc. pursuant to which Viewpoint shareholders will end up owning 49% of the fully diluted outstanding capital stock of Isoray. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the

Business Wire | November 12, 2022

Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

RICHLAND, Wash., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2023 ended September 30, 2022 and provided updates regarding the pending merger with Viewpoint Molecular Targeting.

GlobeNewswire | November 10, 2022

Isoray, Inc. (ISR) Q1 2023 Earnings Call Transcript

Isoray, Inc. (NYSE:NYSE:ISR) Q1 2023 Earnings Conference Call November 10, 2022, 04:30 PM ET Company Participants Mark Levin - IR Lori Woods - CEO Thijs Spoor - CEO, Viewpoint Molecular…

Seeking Alpha | November 10, 2022

Isoray Announces First Quarter Fiscal 2023 Financial Results and Provides Update to Pending Merger

RICHLAND, Wash., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2023 ended September 30, 2022 and provided updates regarding the pending merger with Viewpoint Molecular Targeting. Isoray CEO Lori Woods said the pending merger signifies a watershed moment in the evolution of the company.

Yahoo | November 10, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6277 seconds.